DOCSLIB.ORG

An Abnormal Orosomucoid in the Plasma of Patients with Neoplastic Disease'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Abnormal Orosomucoid in the Plasma of Patients with Neoplastic Disease' [CANCER RESEARCH 32, 1951—1959,September 19721 An Abnormal Orosomucoid in the Plasma of Patients with Neoplastic Disease' Daniel Rudman,2 Perry E. Treadwell, W. Ralph Vogler, Carolyn H. Howard, and Bettye Hollins Departments of Medicine JD. R., W. R. V., C. H. H., B. HI, Biochemistry JD. R./, and Microbiology JP. E. T.J, Emory University School of Medicine, and the ClinicalResearch Facility, Emory University Hospital, A tianta, Georgia 30322 SUMMARY cancer, as it does in those of acute leukemic cases; and (b) to isolate the tryptophan-region material and to determine its Concentrations of the plasma amino acids were measured by chemical structure. As a by-product of this investigation of ion-exchange chromatography in 12 normal subjects (Group tryptophan-region material, further information was accumu I), 10 patients with acute leukemia (Group II), and 38 patients lated on the concentrations of the various plasma amino acids with malignant melanoma or metastatic carcinoma of lung, in patients with neoplastic disease. ovary, or colon (Group III). In Groups II and III, the average concentrations of glutamine, alanine, proline, histidine, and MATERIALS AND METHODS arginine were subnormal. During these analyses, an abnormally elevated peak of ninhydrin-reactive material in the region of Subjects. The subjects studied were 12 normal individuals, the chromatogram ordinarily occupied by tryptophan was ages 23 to 45 (Group I); 10 patients, ages 26 to 53, with acute observed in 75% of the subjects in Groups II and III. However, leukemia (6 lymphocytic and 4 myelocytic) (Group II); and plasma tryptophan concentrations, measured by the specific method of La Du and Michael, were normal. The material 38 patients, ages 26 to 57, with metastatic cancer (Group III). responsible for this peak (“tryptophan-region material―)was The following types of tumor were represented in Group III: isolated by gel-filtration and ion-exchange chromatography. It malignant melanoma (10 patients); bronchogenic carcinoma (9 proved to be a glycoprotein with a molecular weight of 40,000 patients); carcinoma ofthe ovary (10 patients); and carcinoma to 50,000. Its behavior in immunodiffusion, immunoelectro of the colon (9 patients). Individuals were selected for the phoresis, and acrylamide gel electrophoresis at pH 8.9 and 4.0, present study according to the following criteria. First, during and its amino acid composition, were indistinguishable from the period of study, body weight was in the range of ±10%of those of normal human orosomucoid (ct@acid glycoprotein). ideal (calculated according to Metropolitan Life Insurance However, in acrylamide gel electrophoresis at pH 2.7, and in Tables) and did not vary by more than ±1.0 kg/week; food content of hexoses, glucosamine, and sialic acid, the intake amounted to >1200 cal/day (>50 g protein/day). tryptophan-region material isolated from patients in Groups II Second, subjects were afebrile and had no signs of and III differed from normal orosomucoid. Tryptophan-region intercurrent infection when studied. Third, in Groups II material is a form of orosomucoid with a normal protein and III, survival after the analyses reported here was less than moiety but with multiple abnormalities in the carbohydrate I year. Fourthly, in Group III, metastatic involvement of side chains. bone, lung, liver, or lymph nodes had been demonstrated by X-ray or biopsy. Analysis of Plasma Amino Acids. Fasting heparinized blood INTRODUCTION samples were obtained from 7 to 9 a.m. Plasmas were separated within 30 mm and either stored at —20°or We previously described (19) 2 types of abnormality in the processed immediately as specified below. AAN3 was plasma amino acid pattern of most patients with acute measured, on plasma that had been frozen, by the method of leukemia: (a) reduced concentration ofa group of nonessential Frame et a!. (7). Concentrations of individual amino acids amino acids (glutamine, alanine, proline, and histidine); and were measured with lithium citrate buffers by ion-excl@ange (b) a peak of ninhydrin-reactive material in the region of the chromatography in the Beckman 120C instrument, of the 3% ion-exchange chromatogram of the plasma amino acids SSA supernatant fraction offresh plasma (l9).@ Concentration (“aminogram―),ordinarily occupied by tryptophan, but which of tryptophan-region material in plasma is unchanged by other tests showed was not tryptophan. freeze-thawing and by storing at —20°for up to I year. The objectives of the present study were: (a) to learn Plasmas stored at —20°were used, therefore, in most whether tryptophan@region material accumulates in the experiments on isolation and characterization of this material. plasmas of patients with nonleukemic types of advanced Isolation of the Tryptophan-Region Material from Human Plasma. The following procedures were used. For precipitation I This investigation was support@d by USPHS Grants CA 12646-01 3The abbreviations used are: AAN, a-amino nitrogen; SSA, and RR-39. sulfosalicylic acid. 2 To whom requests for reprints should be sent. 4 In selected sera, plasma tryptophan concentration was also Received November 30, 1971; accepted June 2, 1972. measured by the method ofLa Du and Michael(12). SEPTEMBER 1972 1951 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 1972 American Association for Cancer Research. Rudman, Treadwell, Vogler, Howard, and Hollins Table 1 Concentrations in plasma ofcertain amino acids (@imoles/liter),tryptophan-region material (HW units /liter), and AAN (mg/J00 ml) Values represent average ±SE. Concentrations that differ from normal (p < 0.05) are footnoted. Concentrations of the following amino acids did not differ significantly among Groups I, II, and III: threonine, serine, aspartic acid, glutamic acid, asparagine, glycine, valine, cystine, methionine, isoleucine, leucine, tyrosine, phenylalanine, ornithine, and lysine. IIIMalignantBronchogenicCarcinoma Group ofGroup ofCarcinoma colonAminoacid(n IGroup IImelanomacarcinomathe ovarythe =9)Glutamine600 12)(n 10)(n = 10)(n =9)(n=l0)(n 37dProline163 ±54350 ±38°430 ±30b321 ±40C451 ±45435 ± l0'@Alanine315 ±10I 10±11095 ±9c80 ±8'@104 ±II―120 ± 26°Histidine75 ±22167 ±25C250 ±20b181 ±24C195 ±18c200 ± 9°Tryptophanarea2,400± ±347 ±7a55 ±8b10046 ±9d± 600cArginine75 3609,840± 960'@11,900± 830C15,300± 950―13,600± 1010c11,500± @ 8cAAN6.9 ±564 ±838 ±11c43 bc50 ±9°46 ± ±0.085.2 ±0.18―4.9 ±0.26@'5.0 ±o.3oc53 ±0.24@'47 ±0.27c ap < 0.05. b ,, < Cp < 0.005. dp < 0.001. of plasma with SSA, we added to 5 to 20 ml of plasma an (at pH 8.6) (6) were performed against the following antisera equal volume of 6% SSA solution. The mixture was then to human blood fractions, obtained from Hyland and centrifuged at 21,000 X g for 10 mm, and the supernatant Behringwerke Laboratories: rabbit antisera to whole human solution was collected. We then dialyzed various solutions in serum, ct-lipoprotein , transferrin , a2 -haptoglobin , fib rinogen, @ cellophane membranes against distilled H20 for 18 hr at 5°. albumin, 7G-immunoglobulins, Cfi31 A-globulin, ct@-anti Gel filtration of various samples was performed through a 2- x trypsin, a2-HS-glycoprotein, human hemopexin, @32C-glyco 200-cm column of Sephadex G-75 equilibrated with I .0 N protein, and orosomucoid (ct@ acid glycoprotein); horse acetic acid (1 7). “Preparative―5ion-exchangechromatography antisera to fl-lipoprotein and to Gc globulins; and goat was conducted on the short (18-cm) column of the Beckman antiserum to a2 -macroglobulin. In addition, rabbit antisera to 120C amino acid analyzer. The column was programmed for purified samples of tryptophan-region material (labeled analysis of basic amino acids according to Beckman's system “FractionE,―as described under “Results―)wereprepared by for analysis of physiological fluids (22), with the use of injection of this fraction, dissolved in Freund's adjuvant, into sodium citrate buffers. Buffer and temperature changes the rabbit according to the route, dose, and schedule of occurred at 170 mm. Tryptophan eluted at 200 mm. The Campbell et al. (4). sample (5 to 30 mg) was dissolved in 2 ml of sodium citrate The following purified human plasma proteins were buffer, pH 4.5, and was applied to the column. At 185 mm, obtained from Schwarz/Mann Laboratories: albumin, immuno when 154 ml effluent had emerged, the outlet valve was globulin G, fibrinogen, transferrin, and orosomucoid (termed opened into a collecting vessel, and effluent was collected for “commercialorosomucoid―in “Results―). the next 60 mm ; this solution, with a volume of 50 ml, was termed “185-to245-mm fraction.― Characterization of Purified Tryptophan-Region Material. RESULTS The following procedures were used to characterize this material (which proved to be a protein). First, we performed AAN and Aminograms in Patients with Advanced Cancer. acrylamide gel electrophoresis at pH 8.9 , 4.0, and 2 .5 ( I 6). We The level of AAN in the leukemia patients (Group II) and in then measured the amino acid composition (18). Tryptophan the cancer patients (Group III) was significantly lower than content of the protein was determined by the spectrophoto that in the normal subjects (Group 1). Table 1 gives the average metric method of Bencze and Schmid (3). Next, we measured values for each group. In 7 of 10 leukemic cases, and in 30 of the content of hexoses (8), glucosamine, galactosamine [after 38 cancer patients, AAN was more than 2 S.D. below the hydrolysis with 2 N HC1 at 100°for 6 hr under vacuum (22)1, mean of the normals. No gross difference in the frequency of and sialic acid (25). Molecular weight was estimated by gel hypoammnoacidemia in the 4 types of cancer patients was filtration on a calibrated Sephadex G-75 column (17).
Load more

Recommended publications
  • Types of Acute Phase Reactants and Their Importance in Vaccination (Review)
    BIOMEDICAL REPORTS 12: 143-152, 2020 Types of acute phase reactants and their importance in vaccination (Review) RAFAAT H. KHALIL1 and NABIL AL-HUMADI2 1Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307; 2Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA Received May 10, 2019; Accepted November 25, 2019 DOI: 10.3892/br.2020.1276 Abstract. Vaccines are considered to be one of the most human and veterinary medicine. Proteins which are expressed cost-effective life-saving interventions in human history. in the acute phase are potential biomarkers for the diagnosis The body's inflammatory response to vaccines has both of inflammatory disease, for example, acute phase proteins desired effects (immune response), undesired effects [(acute (APPs) are indicators of successful organ transplantation phase reactions (APRs)] and trade‑offs. Trade‑offs are and can be used to predict the ameliorative effect of cancer more potent immune responses which may be potentially therapy (1,2). APPs are primarily synthesized in hepatocytes. difficult to separate from potent acute phase reactions. The acute phase response is a spontaneous reaction triggered Thus, studying acute phase proteins (APPs) during vaccina- by disrupted homeostasis resulting from environmental distur- tion may aid our understanding of APRs and homeostatic bances (3). Acute phase reactions (APRs) usually stabilize changes which can result from inflammatory responses. quickly, after recovering from a disruption to homeostasis Depending on the severity of the response in humans, these within a few days to weeks; however, APPs expression levels reactions can be classified as major, moderate or minor.
    [Show full text]
  • Influence of Infection and Inflammation on Biomarkers of Nutritional Status
    A2.4 INFLUENCE OF INFECTION AND INFLAMMATION ON BIOMARKERS OF NUTRITIONAL STATUS A2.4 Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron David I. Thurnham1 and George P. McCabe2 1 Northern Ireland Centre for Food and Health, University of Ulster, Coleraine, United Kingdom of Great Britain and Northern Ireland 2 Statistics Department, Purdue University, West Lafayette, Indiana, United States of America Corresponding author: David I. Thurnham; [email protected] Suggested citation: Thurnham DI, McCabe GP. Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron. In: World Health Organization. Report: Priorities in the assessment of vitamin A and iron status in populations, Panama City, Panama, 15–17 September 2010. Geneva, World Health Organization, 2012. Abstract n Many plasma nutrients are influenced by infection or tissue damage. These effects may be passive and the result of changes in blood volume and capillary permeability. They may also be the direct effect of metabolic alterations that depress or increase the concentration of a nutrient or metabolite in the plasma. Where the nutrient or metabolite is a nutritional biomarker as in the case of plasma retinol, a depression in retinol concentrations will result in an overestimate of vitamin A deficiency. In contrast, where the biomarker is increased due to infection as in the case of plasma ferritin concentrations, inflammation will result in an underestimate of iron deficiency. Infection and tissue damage can be recognized by their clinical effects on the body but, unfortunately, subclinical infection or inflammation can only be recognized by measur- ing inflammation biomarkers in the blood.
    [Show full text]
  • Ptvg-HP Vaccine Protocol
    Version 10/7/2015 Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) versus GM-CSF Adjuvant in Patients with Non-Metastatic Prostate Cancer CO 08801 Investigational Agent: BB IND 12109 - pTVG-HP DNA encoding human prostatic acid phosphatase Study Sponsors: 56 patients – treated at UWCCC and UCSF Department of Defense Prostate Cancer Research Program federal grant 50 patients in biomarker cohort – treated at UWCCC, UCSF and JHU Madison Vaccines Inc. (MVI) corporate sponsor STUDY SITE INFORMATION Study Sites: University of Wisconsin Carbone Cancer Center (UWCCC) 1111 Highland Avenue Madison, WI 53705 University of California San Francisco (UCSF) Johns Hopkins School of Medicine (JHU) Study Principal Investigator: Douglas G. McNeel, M.D., Ph.D. UWCCC 7007 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel: (608) 263-4198 Fax: (608) 265-0614 [email protected] UWCCC Local Principal Investigator : Glenn Liu, MD UWCCC 7051 Wisconsin Institutes for Medical Research 1111 Highland Ave. Madison, WI 53705 Tel : (608) 265-8689 Fax : (608) 265-5146 [email protected] Medical Monitor: Mark Albertini, M.D. UWCCC 600 Highland Ave. K6/5 CSC Madison, WI 53792 Tel: (608) 265-8131 Fax: (608) 265-8133 [email protected] Other UWCCC Investigators: Joshua Lang, M.D. – Clinical Investigator Christos Kyriakopolous, M.D. – Clinical Investigator Robert Jeraj, Ph.D. – Medical Physics, Quantitative Total Bone Imaging Scott Perlman, M.D. – Nuclear Medicine UCSF Principal Investigator: Lawrence Fong, M.D. JHU Principal Investigator: Emmanuel Antonarakis, MD Study Coordinator: Mary Jane Staab, R.N. B.S.N. UWCCC 600 Highland Ave.
    [Show full text]
  • Role of Myeloid-Derived Suppressor Cells in Tumor-Associated Pregnancy
    MASTER THESIS IN MEDECINE No 747 Role of Myeloid-Derived Suppressor Cells in tumor-associated pregnancy Student Sabine Waeber Tutor Prof. Ivan Stamenkovic Institute of Pathology, CHUV Supervisor Marie-Aude Le Bitoux, Postdoctoral Fellow Expert Prof. Michel Aguet Institute of Pathology, EPFL-ISREC Lausanne, December 2012 1 ABSTRACT 3 INTRODUCTION 4 1. Tumor-host interactions ......................................................................................................................... 4 2. Metastasis during pregnancy .................................................................................................................. 4 3. Immunity & pregnancy ........................................................................................................................... 5 4. MDSC and their potential role in pregnancy .......................................................................................... 5 SPECIFIC AIMS OF THE STUDY 7 RESULTS & DISCUSSION 8 1. Gene expression profiles of MDSC extracted from pregnant mice display features that may augment permissiveness for tumor progression ............................................................................................................. 8 1.1. Results 8 1.1.1. Enrichment of MDSC 8 1.1.2. Hybridization on Affymetrix microarrays 9 1.1.3. Validation of microarray results by qReal-Time RT-PCR 11 1.1.4. Comparison of MDSC genes expressed in pregnant and tumor-bearing mice 12 1.2. Discussion 13 2. MDSC functions during human pregnancy .........................................................................................
    [Show full text]
  • Supplementary Information Changes in the Plasma Proteome At
    Supplementary Information Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease Julia Muenchhoff1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6, Perminder S. Sachdev1,11,* Supplementary Figure S1. Ratios of proteins differentially abundant in asymptomatic carriers of PSEN1 and APP Dutch mutations. Mean ratios and standard deviations of plasma proteins from asymptomatic PSEN1 mutation carriers (PSEN1) and APP Dutch mutation carriers (APP) relative to reference masterpool as quantified by iTRAQ. Ratios that significantly differed are marked with asterisks (* p < 0.05; ** p < 0.01). C4A, complement C4-A; AZGP1, zinc-α-2-glycoprotein; HPX, hemopexin; PGLYPR2, N-acetylmuramoyl-L-alanine amidase isoform 2; α2AP, α-2-antiplasmin; APOL1, apolipoprotein L1; C1 inhibitor, plasma protease C1 inhibitor; ITIH2, inter-α-trypsin inhibitor heavy chain H2. 2 A) ADAD)CSF) ADAD)plasma) B) ADAD)CSF) ADAD)plasma) (Ringman)et)al)2015)) (current)study)) (Ringman)et)al)2015)) (current)study)) ATRN↓,%%AHSG↑% 32028% 49% %%%%%%%%HC2↑,%%ApoM↓% 24367% 31% 10083%% %%%%TBG↑,%%LUM↑% 24256% ApoC1↓↑% 16565% %%AMBP↑% 11738%%% SERPINA3↓↑% 24373% C6↓↑% ITIH2% 10574%% %%%%%%%CPN2↓%% ↓↑% %%%%%TTR↑% 11977% 10970% %SERPINF2↓↑% CFH↓% C5↑% CP↓↑% 16566% 11412%% 10127%% %%ITIH4↓↑% SerpinG1↓% 11967% %%ORM1↓↑% SerpinC1↓% 10612% %%%A1BG↑%%% %%%%FN1↓% 11461% %%%%ITIH1↑% C3↓↑% 11027% 19325% 10395%% %%%%%%HPR↓↑% HRG↓% %%% 13814%% 10338%% %%% %ApoA1 % %%%%%%%%%GSN↑% ↓↑ %%%%%%%%%%%%ApoD↓% 11385% C4BPA↓↑% 18976%% %%%%%%%%%%%%%%%%%ApoJ↓↑% 23266%%%% %%%%%%%%%%%%%%%%%%%%%%ApoA2↓↑% %%%%%%%%%%%%%%%%%%%%%%%%%%%%A2M↓↑% IGHM↑,%%GC↓↑,%%ApoB↓↑% 13769% % FGA↓↑,%%FGB↓↑,%%FGG↓↑% AFM↓↑,%%CFB↓↑,%% 19143%% ApoH↓↑,%%C4BPA↓↑% ApoA4↓↑%%% LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) Supplementary Figure S2.
    [Show full text]
  • Supporting Information for Proteomics DOI 10.1002/Pmic.200401292
    Supporting Information for Proteomics DOI 10.1002/pmic.200401292 Robin Wait, Giulia Chiesa, Cinzia Parolini, Ingrid Miller, Shajna Begum, Daniela Brambilla, Lara Galluccio, Rossana Ballerio, Ivano Eberini, and Elisabetta Gianazza Reference maps of mouse serum acute-phase proteins. Changes with LPS-induced inflammation and apolipoprotein A-I and A-II transgenes ª 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de Reference maps of mouse serum acute-phase proteins. Changes with LPS-induced inflammation and apolipoprotein A-I and A-II transgenes Robin Wait1, Giulia Chiesa2, Cinzia Parolini2, Ingrid Miller5, Shajna Begum1, Daniela Brambilla2, Lara Galluccio2, Rossana Ballerio6, Ivano Eberini2,3,4, and Elisabetta Gianazza2,3,4 1Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, UK 2Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, Milan, Italy 3Gruppo di Studio per la Proteomica e la Struttura delle Proteine, Università degli Studi di Milano, Milan, Italy 4Centro di Eccellenza sulle Malattie del Sistema Nervoso Centrale e Periferico, Università degli Studi di Milano, Milan, Italy 5Institut für Medizinische Chemie, Department für Naturwissenschaften, Veterinärmedizinische Universität Wien, Vienna, Austria 6Centro Cardiologico Monzino, IRCCS, Milan, Italy Correspondence: Dr. Elisabetta Gianazza, Dipartimento di Scienze Farmacologiche, via G. Balzaretti 9, 20133 Milan, Italy E-mail: [email protected] Fax: +39-02-503-18284 Abbreviations: α1G, α1-acid
    [Show full text]
  • ELISA Kit for Hemopexin (HPX)
    SEB986Ra 96 Tests Enzyme-linked Immunosorbent Assay Kit For Hemopexin (HPX) Organism Species: Rattus norvegicus (Rat) Instruction manual FOR IN VITRO AND RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES 11th Edition (Revised in July, 2013) [ INTENDED USE ] The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of hemopexin in rat serum, plasma and other biological fluids. [ REAGENTS AND MATERIALS PROVIDED ] Reagents Quantity Reagents Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard 2 Standard Diluent 1×20mL Detection Reagent A 1×120μL Assay Diluent A 1×12mL Detection Reagent B 1×120μL Assay Diluent B 1×12mL TMB Substrate 1×9mL Stop Solution 1×6mL Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1 [ MATERIALS REQUIRED BUT NOT SUPPLIED ] 1. Microplate reader with 450 ± 10nm filter. 2. Precision single or multi-channel pipettes and disposable tips. 3. Eppendorf Tubes for diluting samples. 4. Deionized or distilled water. 5. Absorbent paper for blotting the microtiter plate. 6. Container for Wash Solution [ STORAGE OF THE KITS ] 1. For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20oC upon receipt while the others should be at 4 oC. 2. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal.
    [Show full text]
  • Tumor Markers
    Tumor Markers Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, Toxicology, Pharmacogenomics Laboratory, SFGH Learning objectives • Know the ideal characteristics of a tumor marker • Understand the role of tumor markers for diagnosis and management of patients with cancer. • Know the emerging technologies for tumor markers • Understand the role of tumor markers for therapeutic selection How do we diagnose cancer today? Physical Examination Blood tests CT scans Biopsy Human Prostate Cancer Normal Blood Smear Chronic Myeloid Leukemia Death rates for cancer vs. heart disease New cancer cases per year Cancer Site or Type New Cases Prostate 218,000 Lung 222,500 Breast 207,500 Colorectal 149,000 Urinary system 131,500 Skin 68,770 Pancreas 43,100 Ovarian 22,000 Myeloma 20,200 Thyroid 44,700 Germ Cell 9,000 Types of Tumor Markers • Hormones (hCG; calcitonin; gastrin; prolactin;) • Enzymes (acid phosphatase; alkaline phosphatase; PSA) • Cancer antigen proteins & glycoproteins (CA125; CA 15.3; CA19.9) • Metabolites (norepinephrine, epinephrine) • Normal proteins (thyroglobulin) • Oncofetal antigens (CEA, AFP) • Receptors (ER, PR, EGFR) • Genetic changes (mutations/translocations, etc.) Characteristics of an ideal tumor marker • Specificity for a single type of cancer • High sensitivity and specificity for cancerous growth • Correlation of marker level with tumor size • Homogeneous (i.e., minimal post-translational modifications) • Short half-life in circulation Roles for tumor markers • Determine risk (PSA)
    [Show full text]
  • LEUKOCYTE SURFACE ORIGIN of HUMAN At-ACID GLYCOPROTEIN (OROSOMUCOID)*
    LEUKOCYTE SURFACE ORIGIN OF HUMAN at-ACID GLYCOPROTEIN (OROSOMUCOID)* BY CARL G. GAHMBERG AND LEIF C. ANDERSSON (From the Department of Bacteriology and Immunology, and the Transplantation Laboratory, Department of Surgery IV, University of Helsinki, Helsinki 29, Finland) Human al-acid glycoprotein (orosomucoid) (o~I-AG)1 constitutes the main component of the seromucoid fraction of human plasma. It belongs to the acute phase proteins, which increase under conditions such as inflammation, pregnancy, and cancer (1, 2). al-AG has previously been found to be synthesized in liver (3), and after removal of terminal sialic acids, it is cleared from the circulation by binding to a receptor protein on liver cell plasma membranes (4). The structure of al-AG is well known. It is composed of a single polypeptide chain and contains 245% carbohydrate including a large amount of sialic acid. The carbohydrate is located in the first half of the peptide chain linked to asparagine residues (5, 6). The function of al-AG is unclear. However, Schmid et al. (5) and Ikenaka et al. (7) and reported that the amino acid sequence of the protein shows a significant homology with human IgG. This finding and the striking increase in inflammatory and lymphopro- liferative disorders made us consider the possibility that leukocytes could be directly involved in the synthesis and release of a~-AG. We report here the presence of a membrane form of al-AG, with an apparent tool wt of 52,000, on normal human lymphocytes, granulocytes, and monocytes. By the use of internal labeling with [3H]leucine in vitro, we demonstrate that the membrane protein is synthesized by lymphocytes.
    [Show full text]
  • Endocrinology Test List Endocrinology Test List
    For Endocrinologists Endocrinology Test List Endocrinology Test List Extensive Capabilities Managing patients with endocrine disorders is complex. Having access to the right test for the right patient is key. With a legacy of expertise in endocrine laboratory diagnostics, Quest Diagnostics offers an extensive menu of laboratory tests across the spectrum of endocrine disorders. This test list highlights the extensive menu of laboratory diagnostic tests we offer, including highly specialized tests and those performed using highly specific and sensitive mass spectrometry detection. It is conveniently organized by glandular function or common endocrine disorder, making it easy for you to identify the tests you need to care for the patients you treat. Comprehensive Care Quest Diagnostics Nichols Institute has been pioneering state-of-the-art endocrine testing for over four decades. Our commitment to innovative diagnostics and our dedication to quality and service means we deliver solutions that enable you to make informed clinical decisions for comprehensive patient management. We strive to remain at the forefront of innovation in endocrine testing so you can deliver the highest level of patient care. Abbreviations and Footnotes NDM, neonatal diabetes mellitus; MODY, maturity-onset diabetes of the young; CH, congenital hyperinsulinism; MSUD, maple syrup urine disease; IHH, idiopathic hypogonadotropic hypogonadism; BBS, Bardet-Biedl syndrome; OI, osteogenesis imperfecta; PKD, polycystic kidney disease; OPPG, osteoporosis-pseudoglioma syndrome; CPHD, combined pituitary hormone deficiency; GHD, growth hormone deficiency. The tests highlighted in green are performed using highly specific and sensitive mass spectrometry detection. Panels that include a test(s) performed using mass spectrometry are highlighted in yellow. For tests highlighted in blue, refer to the Athena Diagnostics website (athenadiagnostics.com/content/test-catalog) for test information.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/25/2021 07:25:24AM Via Free Access 812 M Andreassen and Others EUROPEAN JOURNAL of ENDOCRINOLOGY (2012) 166
    European Journal of Endocrinology (2012) 166 811–819 ISSN 0804-4643 CLINICAL STUDY GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist Mikkel Andreassen1, Jan Frystyk2,3, Jens Faber1,4 and Lars Østergaard Kristensen1 1Endocrine Unit, Laboratory of Endocrinology 54o4, Department of Internal Medicine O, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark, 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark and 3Medical Research Laboratories, Faculty of Health Sciences, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark and 4Faculty of Health Science, Copenhagen University, Copenhagen, Denmark (Correspondence should be addressed to M Andreassen; Email: [email protected]) Abstract Introduction: The GH/IGF1 axis may modulate inflammatory processes. However, the relationship seems complicated as both pro- and anti-inflammatory effects have been demonstrated. Methods/design: Twelve healthy volunteers (mean age 36, range 27–49 years) were treated in random order with increasing doses of GH for 3 weeks (first week 0.01 mg/kg per day, second week 0.02 mg/kg per day, and third week 0.03 mg/kg per day) or a GH receptor antagonist (pegvisomant; first week 10 mg/day and last two weeks 15 mg/day), separated by 8 weeks of washout. Circulating levels of the pro-inflammatory cytokines tumor necrosis factor a (TNFa (TNFA)), interleukin 6 (IL6), and IL1b (IL1B) and the acute phase proteins (APPs) C-reactive protein (CRP), haptoglobin, orosomucoid, YKL40 (CHI3L1), and fibrinogen were measured. Results: During GH treatment, IGF1 (median 131 (Inter-quartile range (IQR) 112–166) vs 390 (322– 524) mg/l, PZ0.002) increased together with TNFa (0.87 (0.74–1.48) vs 1.27 (0.80–1.69) ng/l, PZ0.003), IL6 (1.00 (0.83–1.55) vs 1.35 (0.80–4.28) ng/l, PZ0.045), and fibrinogen (9.2 (8.8–9.6) vs 11.1 (9.4–12.4) mM, PZ0.002).
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]